P1.12-08 The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort

Aquin, T.; Banerji, Shantanu; Bucher, Oliver; Dawe, David E.

doi:10.1016/j.jtho.2018.08.843

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the arrival of new therapeutic strategies, there is an unmet need to understand how baseline patient characteristics influence choice of treatment and clinical outcomes. To date, few real-world studies have comprehensively examined treatment patterns and long-term survival among patients with ES-SCLC in Canada ( 8 , 36 , 37 ). Our group previously evaluated the effect of cisplatin vs. carboplatin on clinical outcomes of a cohort of patients diagnosed with ES-SCLC and LS-SCLC from 2004 to 2013 in Manitoba ( 37 ).…”

Section: Introductionmentioning

confidence: 99%

“…To date, few real-world studies have comprehensively examined treatment patterns and long-term survival among patients with ES-SCLC in Canada ( 8 , 36 , 37 ). Our group previously evaluated the effect of cisplatin vs. carboplatin on clinical outcomes of a cohort of patients diagnosed with ES-SCLC and LS-SCLC from 2004 to 2013 in Manitoba ( 37 ). More patients receiving carboplatin (26.2% of the cohort) had poor ECOG PS, elevated LDH, and ES-SCLC than those receiving cisplatin.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

Dawe,

Rittberg,

Syed

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is an incurable cancer with poor prognosis in which characteristics predictive of long-term survival are debated. The utility of agents such as immune checkpoint inhibitors highlights the importance of identifying key characteristics and treatment strategies that contribute to long-term survival and could help guide therapeutic decisions.ObjectiveThis real-world analysis examines the characteristics, treatment patterns, and clinical outcomes of patients receiving chemotherapy without immunotherapy for ES-SCLC in Manitoba, Canada.MethodsA retrospective cohort study assessed patient characteristics, treatment, and survival duration (short: <6 months; medium: 6–24 months; long: >24 months) using the Manitoba Cancer Registry and CancerCare Manitoba records. Eligible patients were aged >18 years with cytologically confirmed ES-SCLC diagnosed between January 1, 2004, and December 31, 2018, and received cytotoxic chemotherapy (CT). The one-, two-, and five-year probabilities of overall survival (OS) were assessed relative to patient, disease, and treatment characteristics using Kaplan-Meier methods and Cox proportional hazards models.ResultsThis analysis included 537 patients. Cisplatin was used in 56.1% of patients, 45.6% received thoracic radiotherapy (RT), and few received prophylactic cranial irradiation (PCI). In the overall cohort, one-, two- and five-year OS rates were 26%, 8%, and 3%, respectively. For patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, OS rates at one, two, and five years were 43%, 17%, and 10%, respectively, vs. 27%, 8%, and 2% for those with ECOG PS 1–2, and 16%, 3%, and 3% for those with ECOG PS 3–4. In long-term survivors, ECOG PS scores were lower and abnormal laboratory test results were less frequent. Overall, 74.4% of long-term survivors received thoracic RT and 53.5% received PCI. Known poor prognostic factors – including brain/liver metastases, high lactate dehydrogenase (LDH), abnormal sodium, and low hemoglobin levels – were less common but still seen in long-term survivors.ConclusionAlthough rare, patients with ES-SCLC may experience long-term survival with CT ± thoracic RT ± PCI. Factors predicting long-term survival include traditional prognostic factors such as ECOG PS, LDH level, and receipt of thoracic RT or PCI. These findings support current treatment algorithms for ES-SCLC and provide baseline survival estimates to assess the real-world impact of adding immune checkpoint inhibitors in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

Dawe,

Rittberg,

Syed

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The present study expands on our earlier real-world retrospective cohort ( 33 , 34 ), with additional data from patients diagnosed up to the year 2018. The objective of this analysis was to describe the characteristics and treatment regimens of patients with LS-SCLC who received CT ± RT in Manitoba, Canada, and to estimate the probability of OS for these patients to five years from diagnosis.…”

Section: Introductionmentioning

confidence: 93%

“…To date, few population-based studies have comprehensively examined the patient characteristics and treatment patterns associated with long-term survival among patients with LS-SCLC in Canada ( 32 – 34 ). Our group previously evaluated the effect of cisplatin vs. carboplatin on clinical outcomes of patients with ES-SCLC and LS-SCLC in a cohort of patients from CancerCare Manitoba (CCMB) ( 33 ). Patients treated with carboplatin (26.2% of the cohort) were more likely to have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 3−4, elevated lactate dehydrogenase (LDH), and ES-SCLC than those receiving cisplatin.…”

Section: Introductionmentioning

confidence: 99%

“…Patients treated with carboplatin (26.2% of the cohort) were more likely to have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 3−4, elevated lactate dehydrogenase (LDH), and ES-SCLC than those receiving cisplatin. Unadjusted median overall survival (OS) was 224 vs. 322 days in the carboplatin and cisplatin groups, respectively ( 33 ). A separate analysis of the same cohort examined the impact of inpatient vs. outpatient CT administration on outcomes in a mixed group of patients with LS-SCLC and ES-SCLC ( 34 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada

Dawe,

Rittberg,

Syed

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAlthough therapy for limited-stage small-cell lung cancer (LS-SCLC) is administered with curative intent, most patients relapse and eventually die of recurrent disease. Chemotherapy (CT) with concurrent radiotherapy (RT) remains the standard of care for LS-SCLC; however, this could evolve in the near future. Therefore, understanding the current prognostic factors associated with survival is essential.ObjectiveThis real-world analysis examines factors associated with long-term survival in patients with LS-SCLC treated with CT in Manitoba, Canada.MethodsA retrospective cohort study was conducted using Manitoba Cancer Registry and CancerCare Manitoba records. Eligible patients were aged >18 years and had cytologically confirmed LS-SCLC diagnosed between January 1, 2004, and December 31, 2018, for which they received CT ± RT. Baseline patient, disease, and treatment characteristics and survival duration, characterized as short (<6 months), medium (6−24 months), and long term (>24 months), were extracted. Overall survival (OS) was estimated at one, two, and five years and assessed using Kaplan-Meier methods and Cox proportional hazards models.ResultsOver the 15-year study period, 304 patients met the eligibility criteria. Long-term survivors comprised 39.1% of the cohort; at diagnosis, this subgroup was younger, more likely to have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, and have normal lactate dehydrogenase, sodium, and hemoglobin levels. OS estimates for the entire cohort at one, two, and five years were 66%, 38%, and 18%, respectively. In the ECOG PS 0 subgroup, OS estimates at one, two, and five years were 85%, 52%, and 24%, respectively; OS estimates were 60%, 35%, and 17%, respectively, for ECOG PS 1−2 and were 47%, 23%, and 10%, respectively, for ECOG PS 3−4. OS was significantly higher among patients with normal serum sodium and hemoglobin levels than those with abnormal levels. Univariable hazard regression models found that ECOG PS, age at diagnosis, receipt of prophylactic cranial irradiation (PCI), and thoracic RT were associated with survival. On multivariable hazard regression, ECOG PS and receipt of PCI were associated with survival.ConclusionSurvival for greater than two years in patients with LS-SCLC treated with CT ± RT was associated with ECOG PS and receipt of PCI.

show abstract

P1.12-08 The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort

Cited by 2 publications

References 0 publications

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada

Contact Info

Product

Resources

About